Abstract

The use of blood plasma biomarkers in gastric cancer (GC) management is limited due to a lack of reliable biomarkers. An LC-MS/MS assay and a bioinformatic analysis were performed to identify blood plasma biomarkers in a GC discovery cohort. The data obtained were verified and validated by western blotting and an ELISA in an independent study cohort. A label-free quantification analysis of the MS data using PEAKS7 software found that four plasma proteins of apolipoprotein C-1, gelsolin, sex hormone-binding globulin (SHBG), and complement component C4-A were significantly overexpressed in GC patients. A western blot assay of these plasma proteins showed that only SHBG was consistently overexpressed in the patient group. ELISA measurement of SHBG blood plasma levels confirmed that the patient group had significantly higher SHBG levels than the control group. SHBG levels in the patient group remained significantly higher after being stratified by gender, age, and disease stage. These findings show that LC-MS/MS is powerful and highly sensitive for plasma biomarker discovery, and SHBG could be a potential plasma biomarker for GC management.

Original languageEnglish
Pages (from-to)64-74
Number of pages11
JournalCancer Medicine
Volume7
Issue number1
DOIs
Publication statusPublished - Jan 1 2018

Fingerprint

Sex Hormone-Binding Globulin
Stomach Neoplasms
Biomarkers
Blood Proteins
Western Blotting
Enzyme-Linked Immunosorbent Assay
Apolipoproteins C
Gelsolin
Complement C4
Protein C
Computational Biology
Cohort Studies
Software
Control Groups

Keywords

  • Gastric cancer
  • LC-MS/MS
  • SHBG
  • mass spectrometry
  • proteomics

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Sex hormone-binding globulin (SHBG) is a potential early diagnostic biomarker for gastric cancer. / Cheng, Chao Wen; Chang, Che Chang; Patria, Yudha Nur; Chang, Ruei Ting; Liu, Yun Ru; Li, Fu An; Shih, Hsiu Ming; Lin, Ching Yu.

In: Cancer Medicine, Vol. 7, No. 1, 01.01.2018, p. 64-74.

Research output: Contribution to journalArticle

@article{956b8f38a1e64b69b8713cff88bc8fd0,
title = "Sex hormone-binding globulin (SHBG) is a potential early diagnostic biomarker for gastric cancer",
abstract = "The use of blood plasma biomarkers in gastric cancer (GC) management is limited due to a lack of reliable biomarkers. An LC-MS/MS assay and a bioinformatic analysis were performed to identify blood plasma biomarkers in a GC discovery cohort. The data obtained were verified and validated by western blotting and an ELISA in an independent study cohort. A label-free quantification analysis of the MS data using PEAKS7 software found that four plasma proteins of apolipoprotein C-1, gelsolin, sex hormone-binding globulin (SHBG), and complement component C4-A were significantly overexpressed in GC patients. A western blot assay of these plasma proteins showed that only SHBG was consistently overexpressed in the patient group. ELISA measurement of SHBG blood plasma levels confirmed that the patient group had significantly higher SHBG levels than the control group. SHBG levels in the patient group remained significantly higher after being stratified by gender, age, and disease stage. These findings show that LC-MS/MS is powerful and highly sensitive for plasma biomarker discovery, and SHBG could be a potential plasma biomarker for GC management.",
keywords = "Gastric cancer, LC-MS/MS, SHBG, mass spectrometry, proteomics",
author = "Cheng, {Chao Wen} and Chang, {Che Chang} and Patria, {Yudha Nur} and Chang, {Ruei Ting} and Liu, {Yun Ru} and Li, {Fu An} and Shih, {Hsiu Ming} and Lin, {Ching Yu}",
note = "{\circledC} 2017 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.",
year = "2018",
month = "1",
day = "1",
doi = "10.1002/cam4.1254",
language = "English",
volume = "7",
pages = "64--74",
journal = "Cancer Medicine",
issn = "2045-7634",
publisher = "John Wiley and Sons Ltd",
number = "1",

}

TY - JOUR

T1 - Sex hormone-binding globulin (SHBG) is a potential early diagnostic biomarker for gastric cancer

AU - Cheng, Chao Wen

AU - Chang, Che Chang

AU - Patria, Yudha Nur

AU - Chang, Ruei Ting

AU - Liu, Yun Ru

AU - Li, Fu An

AU - Shih, Hsiu Ming

AU - Lin, Ching Yu

N1 - © 2017 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - The use of blood plasma biomarkers in gastric cancer (GC) management is limited due to a lack of reliable biomarkers. An LC-MS/MS assay and a bioinformatic analysis were performed to identify blood plasma biomarkers in a GC discovery cohort. The data obtained were verified and validated by western blotting and an ELISA in an independent study cohort. A label-free quantification analysis of the MS data using PEAKS7 software found that four plasma proteins of apolipoprotein C-1, gelsolin, sex hormone-binding globulin (SHBG), and complement component C4-A were significantly overexpressed in GC patients. A western blot assay of these plasma proteins showed that only SHBG was consistently overexpressed in the patient group. ELISA measurement of SHBG blood plasma levels confirmed that the patient group had significantly higher SHBG levels than the control group. SHBG levels in the patient group remained significantly higher after being stratified by gender, age, and disease stage. These findings show that LC-MS/MS is powerful and highly sensitive for plasma biomarker discovery, and SHBG could be a potential plasma biomarker for GC management.

AB - The use of blood plasma biomarkers in gastric cancer (GC) management is limited due to a lack of reliable biomarkers. An LC-MS/MS assay and a bioinformatic analysis were performed to identify blood plasma biomarkers in a GC discovery cohort. The data obtained were verified and validated by western blotting and an ELISA in an independent study cohort. A label-free quantification analysis of the MS data using PEAKS7 software found that four plasma proteins of apolipoprotein C-1, gelsolin, sex hormone-binding globulin (SHBG), and complement component C4-A were significantly overexpressed in GC patients. A western blot assay of these plasma proteins showed that only SHBG was consistently overexpressed in the patient group. ELISA measurement of SHBG blood plasma levels confirmed that the patient group had significantly higher SHBG levels than the control group. SHBG levels in the patient group remained significantly higher after being stratified by gender, age, and disease stage. These findings show that LC-MS/MS is powerful and highly sensitive for plasma biomarker discovery, and SHBG could be a potential plasma biomarker for GC management.

KW - Gastric cancer

KW - LC-MS/MS

KW - SHBG

KW - mass spectrometry

KW - proteomics

UR - http://www.scopus.com/inward/record.url?scp=85034231700&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85034231700&partnerID=8YFLogxK

U2 - 10.1002/cam4.1254

DO - 10.1002/cam4.1254

M3 - Article

VL - 7

SP - 64

EP - 74

JO - Cancer Medicine

JF - Cancer Medicine

SN - 2045-7634

IS - 1

ER -